Back to Search
Start Over
Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma
- Publication Year :
- 2024
-
Abstract
- Weily Soong,1 Bradley E Chipps,2 Warner Carr,3 Jennifer Trevor,4 Arpan Patel,5 Nicole Clarke,6 Donna D Carstens,5 Christopher S Ambrose6 1AllerVie Health, AllerVie Clinical Research, Birmingham, AL, USA; 2Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA; 3Allergy & Asthma Associates of Southern California, Food Allergy Center of Southern California, Mission Viejo, CA, USA; 4Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 5BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 6BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USACorrespondence: Christopher S Ambrose, BioPharmaceuticals Medical, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA, Tel +1 301-398-4454, Email chris.ambrose@astrazeneca.comPurpose: Patients living with severe asthma (SA) experience multiple health-related quality of life (HRQoL) impairments. This study examined HRQoL changes after biologic treatment initiation among a large, real-world cohort of patients with SA.Patients and methods: CHRONICLE is an ongoing observational study of subspecialist-treated adults with SA who receive biologics or maintenance systemic corticosteroids or are uncontrolled on high-dosage inhaled corticosteroids with additional controllers. Patients enrolled February 2018âFebruary 2023 were asked to complete the St. Georgeâs Respiratory Questionnaire (SGRQ) every 6 months (total score range of 0â 100 [0=best possible health], meaningful change threshold is a 4-unit reduction in the total score). Changes in SGRQ responses from 6 months before initiation to 12 to 18 months after initiation were summarized.Results: A total of 76 patients completed the SGRQ 0 to 6 months before and 12 to 18 months after biologic initiation. The mean (SD) SGRQ total score decreased from 52.2 (20.6) to 41.9 (23.8), with improvement across the symptoms (â 14.5), activity (â 11.0), and impacts (â 8.3) componen
Details
- Database :
- OAIster
- Notes :
- text/html, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1446976768
- Document Type :
- Electronic Resource